Diabetes Care Clinical Trial
Official title:
Investigation of a Sub-Conjunctival Insert
| Verified date | October 2011 |
| Source | EyeSense GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Germany: Federal Institute for Drugs and Medical Devices |
| Study type | Interventional |
The study is intended to evaluate a non-invasive method of glucose measurement in diabetics. The medical device that is evaluated consists on a sensor-insert which is placed under the conjunctiva of the eye of diabetic patients and a photometer. The goal is to prove that the sensor signal correlates with the blood glucose of the patients determined by standard laboratory blood glucose measurement.
| Status | Terminated |
| Enrollment | 28 |
| Est. completion date | May 2013 |
| Est. primary completion date | March 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Be of legal age - Insulin dependent diabetes requiring daily finger pricking to monitor blood glucose - Sign written Informed Consent Exclusion Criteria: - Inability to follow the protocol schedule - Participating in another clinical study - Pregnant or lactating females - Any ongoing condition that would prevent from proper handling of the instrument (e.g. blindness, strong impaired vision, impaired motor skills) - Any known hypersensitivity to any of the products to be used in the study, including preservatives etc. - Malignancies requiring therapy during the study - Severe chronic diseases e.g. renal failure, liver cirrhosis etc. which may interfere with the conduct or completion of the study - Poorly controlled diabetes mellitus with prior hemoglobin A1C greater than 10% - Any ocular disease requiring topical medication besides those permitted by this protocol. - Ocular or other condition which increase the risk of ocular surgery, e.g. acute or chronic conjunctivitis or blepharitis, corneal disorders, previous eye surgery or eye surgery within the following 12 weeks, coagulation disorders. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| Germany | Diabetes Instiut Heidelberg | Heidelberg |
| Lead Sponsor | Collaborator |
|---|---|
| EyeSense GmbH |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | short term and mid term performance of different versions of the insert | at 1 month, at 2 months, at 3 months | Yes | |
| Primary | recovery from surgery (wound healing) | at 1 month, at 2 months, at 3 months | Yes | |
| Primary | demonstrate correlation between the fluorescence reading of the insert and capillary blood glucose measurement | at 1 month, at 2 months, at 3 months | No | |
| Secondary | subjective impressions | 1 year | Yes | |
| Secondary | lag time between blood glucose and interstitial fluid glucose | at 1 month, at 2 months, at 3 months | No | |
| Secondary | signal to noise ration, signal drift and stability of measurement | at 1 month, at 2 months, at 3 months | No | |
| Secondary | conjunctival hyperemia | at 1 month, at 2 months, at 3 months | Yes | |
| Secondary | duty of care | at 1 month, at 2 months, at 3 months | Yes |